Home
>
US Stocks
>
Humanigen Inc
Humanigen Inc
HGEN

Humanigen Inc (HGEN)

$6.4563.83%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
6.33
Today Low/High
6.2 / 6.45
52 Week Low/High
$7.75 / $29.2
Market Cap
$944.56M

Company Details

Humanigen, Inc. is developing its portfolio of Humaneered® monoclonal antibodies to address cutting-edge CAR-T optimization and oncology treatments advancing safer, better, and more effective cancer therapies. Derived from the company's Humaneered® platform, lenzilumab and ifabotuzumab are monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets GM-CSF, is in development as a potential biologic therapy to make CAR-T therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as CMML and JMML. Ifabotuzumab, which targets the Eph type-A receptor 3 (EphA3), is being explored as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers, both as naked antibody and as part of an antibody-drug conjugate, as well as a backbone for a novel CAR-T construct, and a bispecific antibody platform.
Organisation
Humanigen Inc
Headquaters
Burlingame, California, US
Employees
10
Industry
Biotechnology
CEO
Cameron Durrant

Discover more

Frequently Asked Questions

What is Humanigen Inc (HGEN) share price today?

Can Indians buy Humanigen Inc (HGEN) shares?

How can I buy Humanigen Inc (HGEN) shares from India?

Can Fractional shares of Humanigen Inc (HGEN) be purchased?

What are the documents required to start investing in Humanigen Inc (HGEN) stocks?

We are a SEBI registered investement advisor